Ovette Villavicencio, MD, PHD - Catalina Eye Care
526
page-template-default,page,page-id-526,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-16.5,qode-theme-bridge,wpb-js-composer js-comp-ver-5.5.2,vc_responsive
 

Ovette Villavicencio, MD, PHD

Dr. Ovette Villavicencio

Dr. Ovette Villavicencio is a board certified and fellowship-trained ophthalmologist who specializes in minimally-invasive corneal transplant surgery, vision correction with advanced technology cataract surgery, and the medical and surgical treatment of corneal and external disease, including Fuchs’ endothelial dystrophy, Keratoconus and is trained in all disciplines of comprehensive ophthalmology. A Magna Cum Laude graduate of Illinois Wesleyan University with a B.A. degree in chemistry and business administration, Dr. Villavicencio earned his Doctor of Philosophy with a concentration on optical storage materials and Doctor of Medicine degrees at the University of Arizona. After completing a medical internship and ophthalmology residency at the University of Arizona, he went on to complete a fellowship in corneal transplantation, refractive surgery, and external ophthalmic diseases at the prestigious Price Vision Group in Indianapolis, IN.

Dr. Villavicencio’s training included all facets of corneal transplantation including the revolutionary Descemet’s Membrane Endothelial Keratoplasty (DMEK), an ultra-thin partial thickness corneal transplant for the treatment of Fuchs’ Dystrophy and other corneal diseases that target the diseased layers of the cornea and preserve as much of the healthy cornea as possible. He has authored textbook chapters and journal articles on DMEK and has taught the procedure to established surgeons from around the world and also serves as an advisor to eye banks for the processing of the transplant tissue. He also performs Deep Anterior Lamellar Keratoplasty (DALK), full thickness corneal transplants, and keratoprostheses.

Dr. Villavicencio and Catalina Eyecare are excited to offer the FDA-approved treatment of keratoconus using Corneal Collagen Cross-Linking, which can slow or even stop the progression of keratoconus. Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has recently received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL Collagen Cross-Linking System. Dr. Villavicencio is proud to have been part of a nationwide team involved in the Avedro study, which resulted in the FDA approval of this new device and treatment. Dr. Villavicencio has been performing Collagen Cross-Linking since 2014, as part of the KXL Study in Indianapolis, IN. Since late 2016, Dr. Villavicencio has been offering this technology to the Tucson and Southern Arizona area.

Dr. Villavicencio is a diplomat of the American Board of Ophthalmology and a member of the American Academy of Ophthalmology, American Society of Cataract & Refractive Surgeons, and the Cornea Society, among other professional societies. Dr. Villavicencio is also an Assistant Clinical Professor of Ophthalmology at the University of Arizona where he is involved in the surgical and clinical training of the resident physicians.